NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









PL BioScience

PL BioScience

Private
AachenHealthcare & Life Scienceshttps://pl-bioscience.com/

Last Round

Series A

Aug 12, 2024

Total Funding Raised

$13.06M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

PL BioScience is a biotechnology company that develops and manufactures animal-free cell culture media, specifically Human Platelet Lysate (HPL), for use in regenerative medicine, cell therapy, and biopharmaceutical research.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

hPLhuman platelet lysatecell culture supplementcell culture mediaanimal-free mediaregenerative medicinecell therapyxeno-free mediafetal bovine serum alternativeFBS alternativeGMP-grade reagentsbioprocessingcell expansionbiotechnology manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PL BioScience Comparables

Compare PL BioScience with similar companies based on industry and business-model similarity.

PL BioScience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mill Creek Life Sciences
87%
AventaCell BioMedical Corp.
86%
Compass Biomedical
84%

PL BioScience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AAug 12, 2024
SeedMay 21, 2021

Key People

Founding team and executive leadership

Hatim Hemeda

CEO Founder

Founding Team

Oliver Dick

CTO

Executive Team

PL BioScience Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 20, 2026

    Exclusive agreement with Summit Pharmaceuticals International Corporation for the Japanese market.

  • Dec 22, 2025

    Added Iwai Chem, a chemicals/life sciences distributor, as a customer.

PL BioScience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

PL BioScience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PL BioScience's valuation, stock price, and market status.

Firmographic Details

HeadquartersAachen
Employee Range36
Year Founded2015
Last FundingAug 12, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.